GSK, Daiichi Sankyo establish new vaccine JV in Japan
Linkedin

GSK, Daiichi Sankyo establish new vaccine JV in Japan

New York City : NY : USA | Mar 04, 2012 at 9:50 PM PST
Source: Pharmaceutical Industry News
XX XX
Views: Pending
 
The JV is responsible for development and commercial rights of prophylactic vaccines. The companies will invest equally in the JV and the transaction is expected to be completed in third quarter 2012, subject to local regulatory approvals. Japan Vaccine will contribute to improving access to vaccines... FULL ARTICLE AT Pharmaceutical Industry News
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
Advertisement
 
Advertisement
 

News Stories

 
  • A.M. Vitals: Daiichi Sankyo, GlaxoSmithKline Form Vaccine Venture

    WSJ.com: Health Blog
    Daiichi Sankyo and GlaxoSmithKline are teaming up to develop and market vaccines in Japan, the WSJ reports . Each company will hold a 50% share in the Japan Vaccine Co. venture, which will have an initial capitalization of $1.2 million and will begin...

More From Allvoices

 
Tap_logo_330_110_event
 


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2013. All rights reserved.